EcoDrugPlus

Ret Proto-Oncogene

Ensembl ID : ENSSAUG00010021734
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSSAUG00010005778
Gene Symbol: LOC115567545
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSSAUG00010014933
Gene Symbol: RARB
1 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSSAUG00010015983
Gene Symbol: LOC115567051
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSSAUG00010019607
Gene Symbol: RARG
3 Cross references
353 Possible Orthologues:

Retinoic Acid Receptor Gamma-A-Like

Ensembl ID : ENSSAUG00010024248
Gene Symbol: LOC115583205
3 Cross references
377 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSSAUG00010009419
Gene Symbol: RXRA
3 Cross references
225 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 2b

Ensembl ID : ENSSAUG00010015365
Gene Symbol: ROCK2B
1 Cross references
225 Possible Orthologues:

Ribosomal Protein L10

Ensembl ID : ENSSAUG00010022951
Gene Symbol: RPL10
3 Cross references
405 Possible Orthologues:

Ribosomal Protein L10a

Ensembl ID : ENSSAUG00010025284
Gene Symbol: RPL10A
3 Cross references
366 Possible Orthologues:

Ribosomal Protein L11

Ensembl ID : ENSSAUG00010026633
Gene Symbol: RPL11
3 Cross references
288 Possible Orthologues:

Ribosomal Protein L12

Ensembl ID : ENSSAUG00010018685
Gene Symbol: RPL12
3 Cross references
476 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).